By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Roches Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Health

Roches Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

GlobeNews Wire
Last updated: 13/12/2024 3:54 PM
GlobeNews Wire
Share
11 Min Read
Roches Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
SHARE
Roches Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
  • Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vials
  • Vabysmo has demonstrated rapid and robust vision and anatomical improvements in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO)
  • The ready-to-use Vabysmo PFS is co-packaged with the only CE-marked needle specifically designed for intravitreal injection

Basel, 13 December 2024– Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect more than nine million people in the European Union (EU) and can have a devastating impact – physically, emotionally, and economically – on those affected, their families and caregivers.1-5

“Approval of the Vabysmo prefilled syringe in the EU offers a convenient way for ophthalmologists to administer this treatment for people with three of the most common causes of vision loss,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “This simplified administration may thereby help reduce the treatment burden for patients and retina specialists.”

The Vabysmo PFS provides ophthalmologists with the first and only CE-labelled needle for intravitreal injection. Vabysmo PFS delivers the same medicine as the currently available 6.0 mg Vabysmo vials in an alternative, ready-to-use format.6 More than five million doses of Vabysmo have been distributed globally since its initial US approval in 2022.6-11 Vabysmo PFS was first approved for nAMD, DME and RVO by the United States Food and Drug Administration in July 2024.7 Vabysmo PFS will be the European Union’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness.  

About Vabysmo® (faricimab)
Vabysmo is the first bispecific antibody approved for the eye.7,8,12 It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.12,13 Vabysmo is approved in more than 100 countries around the world, including the United States (US), Japan, the United Kingdom and the European Union (EU) for people with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema, and in more than 30 countries, including the US, EU and Japan, for people with macular edema following retinal vein occlusion. Review by other health authorities is ongoing.6-11

About Roche in Ophthalmology
Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients.

We have the broadest retina pipeline in ophthalmology, which is led by science and informed by insights from people with eye diseases. Our pipeline includes innovative treatments across different modalities, such as antibodies, and gene and cell therapies targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema.

Applying our extensive experience, we have already brought breakthrough ophthalmic treatments to people living with vision loss. Susvimo® (previously called Port Delivery System with ranibizumab) 100 mg/mL for intravitreal use via ocular implant is the first United States Food and Drug Administration-approved refillable eye implant for neovascular or ‘wet’ age-related macular degeneration that continuously delivers a customised formulation of ranibizumab over a period of months.14,15 Vabysmo® (faricimab) is the first bispecific antibody approved for the eye, which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 and vascular endothelial growth factor-A.7,8,12,13 Vabysmo is approved around the world for people living with nAMD, diabetic macular edema and macular edema following retinal vein occlusion.6-11 Lucentis® (ranibizumab injection)* was the first treatment approved to improve vision in people with certain retinal conditions.16 

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

*Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world.

All trademarks used or mentioned in this release are protected by law.

References
[1] National Institute for Health and Care Excellence. Macular degeneration – age-related: how common is it? [Internet; cited December 2024]. Available from:

https://cks.nice.org.uk/topics/macular-degeneration-age-related/background-information/prevalence

.
[2] Bright Focus Foundation. Age-related macular degeneration: facts & figures. [Internet; cited December 2024]. Available from:

https://www.brightfocus.org/macular/article/age-related-macular-facts-figures

.
[3] European Commission. Diabetes prevention. [Internet; cited December 2024]. Available from:

https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/diabetes-prevention

.
[4] Im JHB, et al. Prevalence of diabetic macular edema (DME) based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Survey of Ophthalmology. 2022 Jul-Aug;67(4):1244-1251.
[5] Li JQ, et al. Prevalence of retinal vein occlusion (RVO) in Europe: a systematic review and meta-analysis. Ophthalmologica. 2019;241(4):183-189.
[6] European Medicines Agency. Summary of product characteristics, Vabysmo. 2024. [Internet; cited December 2024]. Available from:

https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf

.
[7] United States (US) Food and Drug Administration (FDA). Highlights of prescribing information, Vabysmo. 2024 [Internet; cited December 2024]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761235s005lbl.pdf

.
[8] Medicines and Healthcare products Regulatory Agency approves faricimab through international work-sharing initiative. [Internet; cited December 2024]. Available from:

 https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative

.
[9] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited December 2024]. Available from:

 https://www.chugai-pharm.co.jp/english/news/detail/20240326160000_1054.html

.
[10] Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, neovascular age-related macular degeneration (nAMD) and DME. [Internet; cited December 2024]. Available from:

 https://www.chugai-pharm.co.jp/english/news/detail/20220328160002_909.html

.
[11] Roche data on file.
[12] Heier JS, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for nAMD (TENAYA and LUCERNE): two randomised, double-masked, phase III, non-inferiority trials. The Lancet. 2022; 399:729-40.
[13] Wykoff C, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with DME (YOSEMITE and RHINE): Two randomised, double-masked, phase III trials. The Lancet. 2022; 399:741-755.
[14] US FDA. Highlights of prescribing information, Susvimo. 2021. [Internet; cited December 2024]. Available from: 

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf

.
[15] Holekamp N, et al. Archway randomised phase III trial of the Port Delivery System with ranibizumab for nAMD. Ophthalmology. 2021.
[16] US FDA. Highlights of prescribing information, Lucentis. 2014. [Internet; cited December 2024]. Available from:

 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf

. 

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 79 407 72 58
Sileia Urech
Phone: +41 79 935 81 48
Nathalie Altermatt
Phone: +41 79 771 05 25
Lorena Corfas
Phone: +34 620 29 25 51
Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83
Nina Mählitz
Phone: +41 79 327 54 74
Kirti Pandey
Phone: +49 172 6367262
Yvette Petillon
Phone: +41 79 961 92 50
Dr Rebekka Schnell
Phone: +41 79 205 27 03

Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
 

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
 
  • 13122024_MR_EU approval_Vabysmo PFS_en

You Might Also Like

Avicanna Announces Closing of Non-Brokered Private Placement

Greaves Cotton Ltd. Showcases Innovative product and services to Build the complete Mobility Ecosystem at The Auto Expo 2025- The Motor Show

Labor Day Weekend in Las Vegas Promises a Fantastic Lineup of Entertainment, Sports and More

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Catheter Precision, Inc. Receives CE Mark for LockeT

TAGGED:administrationannouncedapprovalapprovedbaselblindnesscancauseconditionsdecemberdmeedemaeuropeanfirstmacularmillionnamdophthalmologistsotcqxpeoplepfsprefilledretinalrhhbyrocherochesrogrvosixsyringethatthreetodaytreatmentuncategorizedvabysmo

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Strategic Realignment: OQ Chemicals Sells Dutch Esters Plant to Perstorp Group Strategic Realignment: OQ Chemicals Sells Dutch Esters Plant to Perstorp Group
Next Article New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

MEXC Hits 40M Users with 46% Growth in New Listing Token Trading Volume in May
MEXC Hits 40M Users with 46% Growth in New Listing Token Trading Volume in May
Business 09/06/2025
BingX and Chelsea FC Unveil 25/26 Training Kit with “Trained on Greatness” Campaign
BingX and Chelsea FC Unveil 25/26 Training Kit with “Trained on Greatness” Campaign
Business 09/06/2025
Quantel Asset Management and Sincere Syndication Announce Strategic Partnership to Unlock U.S.-India Cross-Border Investment Opportunities
Quantel Asset Management and Sincere Syndication Announce Strategic Partnership to Unlock U.S.-India Cross-Border Investment Opportunities
Business 09/06/2025
$ZEUS Announces the Next Era: Trademark Secured, Artist Doxxed, Legacy Unleashed
$ZEUS Announces the Next Era: Trademark Secured, Artist Doxxed, Legacy Unleashed
Tech 09/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?